Novus Therapeutics Inc (NASDAQ:NVUS) President Catherine C. Turkel sold 9,537 shares of Novus Therapeutics stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $1.95, for a total value of $18,597.15. Following the completion of the transaction, the president now directly owns 90,576 shares of the company’s stock, valued at $176,623.20. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Novus Therapeutics stock traded up $0.02 during midday trading on Friday, reaching $1.73. The stock had a trading volume of 27,675 shares, compared to its average volume of 45,017. Novus Therapeutics Inc has a 12 month low of $1.52 and a 12 month high of $8.61. The firm has a market capitalization of $16.13 million, a price-to-earnings ratio of -1.11 and a beta of 3.32. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.18 and a quick ratio of 3.18.
Novus Therapeutics (NASDAQ:NVUS) last issued its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). On average, sell-side analysts expect that Novus Therapeutics Inc will post -1.61 EPS for the current year.
NVUS has been the subject of several research analyst reports. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $10.00 price objective on shares of Novus Therapeutics in a research report on Wednesday, May 15th. ValuEngine raised Novus Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, February 25th. Finally, Zacks Investment Research raised Novus Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday.
Novus Therapeutics Company Profile
Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection).
See Also: Market Perform
Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.